Investors OrbiMed and Foresite say they’re looking at taking Kinnate private, following pipeline and staff cuts

Kinnate Biopharma’s stock $KNTE soared 59% on Wednesday afternoon after the California drug developer disclosed that two large shareholders have expressed interest in a take-private deal.

OrbiMed and Foresite — which own about 29% and 17% of Kinnate’s…
Click here to view original post